{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:52:40Z","timestamp":1758394360328,"version":"3.44.0"},"reference-count":10,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,8,11]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>Nivolumab is an immune checkpoint inhibitor acting on programmed cell death protein 1 (PD-1) that has been used to treat a growing number of malignancies. Cutaneous side effects are common with nivolumab treatment, though they are typically self-limited. Here we present a case of persistent lichenoid dermatitis in a patient treated with nivolumab for renal cell cancer. The patient then developed Stevens-Johnson syndrome 9\u2009months after initiation of nivolumab, with no other identifiable offending medication in the interim. Although an unusual presentation, a growing number of cases have reported delayed Stevens-Johnson syndrome\/toxic epidermolytic necrosis-like reactions to immune checkpoint inhibitors. Awareness of this phenomenon is imperative for prompt recognition and treatment of potentially life-threatening cutaneous side effects.<\/jats:p>","DOI":"10.1136\/bcr-2022-251233","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:01:07Z","timestamp":1661511667000},"page":"e251233","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Lichenoid dermatitis preceding Stevens-Johnson syndrome in a patient treated with nivolumab"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1823-3676","authenticated-orcid":false,"given":"Jolee","family":"Potts","sequence":"first","affiliation":[{"name":"Internal Medicine, Mercy Hospital St Louis Area, St Louis, Missouri, USA"},{"name":"Dermatology, Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel Raven","family":"Lee","sequence":"additional","affiliation":[{"name":"Internal Medicine, Mercy Hospital St Louis Area, St Louis, Missouri, USA"},{"name":"Infectious Disease, George Washington University School of Medicine & Health Sciences, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn A","family":"Hilliard","sequence":"additional","affiliation":[{"name":"Internal Medicine, Mercy Hospital St Louis Area, St Louis, Missouri, USA"},{"name":"Internal Medicine, SSM Saint Louis University, St. Louis, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"2025082710565132000_15.8.e251233.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"2025082710565132000_15.8.e251233.2","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025082710565132000_15.8.e251233.3","first-page":"1259","article-title":"Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag Red"},{"key":"2025082710565132000_15.8.e251233.4","doi-asserted-by":"crossref","first-page":"100951","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025082710565132000_15.8.e251233.5","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230538","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: treatment with low-dose corticosteroids, vitamin C and thiamine","volume":"12","author":"Middendorf","year":"2019","journal-title":"BMJ Case Rep"},{"key":"2025082710565132000_15.8.e251233.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2872"},{"key":"2025082710565132000_15.8.e251233.7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdx640","article-title":"Stevens-Johnson syndrome during nivolumab treatment of NSCLC","volume":"29","author":"Salati","year":"2018","journal-title":"Ann Oncol"},{"key":"2025082710565132000_15.8.e251233.8","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"2025082710565132000_15.8.e251233.9","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1177\/1078155219830166","article-title":"Late-Onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma","volume":"25","author":"Dasanu","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025082710565132000_15.8.e251233.10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-251233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:56:58Z","timestamp":1756317418000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-251233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":10,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8,26]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bcr-2022-251233"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-251233","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}